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A B S T R A C T
Background
Neonatal extracorporeal membrane oxygenation (ECMO) is a complex procedure of life support used in severe but potentially reversible
respiratory failure in term infants. Although the number of babies eligible for ECMO is small and the use of ECMO invasive and
potentially expensive, its benefits may be high.
Objectives
To determine whether ECMO used for neonatal infants with severe respiratory failure is clinically and cost effective compared to
conventional ventilatory support.
Search methods
The Cochrane Neonatal Group Specialised Register, the Cochrane Controlled Trials Register, and MEDLINE were searched for 1974
to 2007.
Selection criteria
All randomised trials comparing neonatal ECMO to conventional ventilatory support.
Data collection and analysis
The authors independently evaluated the trials for methodological quality and appropriateness for inclusion in the Review (without
consideration of their results) and independently extracted the data.
Main results
The four trials (three USA and one UK) recruited clinically similar groups of babies. Two trials excluded infants with congenital
diaphragmatic hernias. In two trials, transfer for ECMO implied transport over long distances. Two trials had follow-up information.
One study included economic evaluation.
The three USA trials had very small numbers of patients. Two trials used conventional randomisation with low potential for bias. Two
used less usual designs, which led to difficulties in their interpretation.
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All four trials showed strong benefit of ECMO on mortality (typical RR 0.44; 95% CI 0.31 to 0.61), especially for babies without
congenital diaphragmatic hernia (typical RR 0.33, 95% CI 0.21 to 0.53).
The UK trial provided follow up information about death or severe disability, and cost-effectiveness, and showed benefit of ECMO
at one year (RR 0.56, 95% CI 0.40 to 0.78), four years (RR 0.62, 95% CI 0.45 to 0.86), and seven years (RR 0.64, 95% CI 0.47 to
0.86). Overall nearly half of the children recruited had died or were severely disabled by seven years of age, reflecting the severity of
their underlying conditions. A policy of ECMO is as cost-effective as other intensive care technologies in common use.
Authors’ conclusions
A policy of using ECMO in mature infants with severe but potentially reversible respiratory failure results in significantly improved
survival without increased risk of severe disability. The benefit of ECMO for babies with diaphragmatic hernia is unclear.
Further studies are needed to consider the optimal timing for introducing ECMO; to identify which infants are most likely to benefit;
and to address the implications of neonatal ECMO during later childhood and adult life.
P L A I N L A N G U A G E S U M M A R Y
Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
A complex life support procedure, called extracorporeal membrane oxygenation (ECMO), can be used in infants who are near term age
to overcome severe, potentially reversible breathing problems. ECMO is similar to the technology used in cardiac bypass surgery. Blood
is removed from the body of the patient, oxygen is added to the blood, and the blood is returned to the patient. Although the number
of babies requiring ECMO is small, and ECMO is a very invasive and potentially expensive procedure, the benefits of this procedure
are high. In this review, four randomized trials that compared the use of ECMO to the conventional approach to supporting these
infants with severe breathing problems were identified. Overall, these trials showed a strong benefit for ECMO regarding survival at the
time of hospital discharge. This is particularly true for infants without a specific problem of lung formation (congenital diaphragmatic
hernia). The result implies that for every three babies with breathing problems and lung failure who were treated with ECMO rather
than conventional ventilation, one more infant will survive. Although little information is available regarding long-term follow-up, one
trial in the United Kingdom shows both benefits of ECMO and cost-effectiveness of the use of ECMO.
B A C K G R O U N D
Extracorporeal membrane oxygenation (ECMO) is a complex
technique for providing life support in severe but potentially re-
versible respiratory failure. The technique oxygenates blood out-
side the body, obviating the need for gas exchange in the lungs and,
if necessary, provides cardiovascular support. It is most commonly
used to support mature newborn infants, as preterm infants are
not suitable both because of the size of the cannulae required, and
because of their additional risk of intraventricular haemorrhage
associated with the use of heparin.
The concept arose as an off-shoot of cardiopulmonary by-pass
technology. Initially it was used to support adults, but early re-
sults were poor. Similarly, early attempts to use ECMO in the
treatment of newborns were unsuccessful; cannula problems pro-
vided the greatest technical difficulty.However, in 1975Bartlett re-
ported the first mature newborn treated successfully with ECMO
and other reports soon followed (Bartlett 1976). It subsequently
became clear that mature infants with persistent pulmonary hy-
pertension of the newborn (PPHN) were particularly suited to
ECMO, since the better oxygenation and physiological stability
produced by ECMO improved pulmonary blood flowwithout the
risk of further barotrauma.
ECMO is an extremely invasive and technically involved pro-
cedure. Traditional ECMO uses two large gauge catheters, one
placed in a central vein and the other in a central artery (veno-
arterial or V-A). It is essential to achieve adequate flow rates (ap-
proximately 100 - 120 ml/kg/min) and as a result cannulae are
normally 12 - 14 French gauge. Blood is drained passively via the
venous catheter which is inserted into the internal jugular vein
and positioned in the right atrium. Blood then passes on to a
pump which maintains flow in the circuit. A ’bladder box’ and
servo system prevent the pump from working if venous drainage
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becomes inadequate for any reason. Blood then passes to an oxy-
genator where a sweep gas passes in counter current to the blood.
The concentration of oxygen in the sweep gas can be adjusted de-
pending on the needs of the patient. Before re-entering the body,
warming occurs in a heat exchange column. Blood is returned
via the common carotid artery at systemic pressure. This type of
ECMO is able to support both pulmonary and cardiac function.
More recently, veno-venous (V-V) ECMO, which provides just
pulmonary support, has become popular and is now used increas-
ingly. The particular, theoretical, advantage of V-V ECMO is that
the cerebral arterial blood supply is not disrupted.
While on ECMO additional gas exchange by the lungs is not
essential and therefore ventilation is normally reduced to ’rest’
settings. This is typically 5 - 10 cm H2O positive end expiratory
pressure and 10 to 20 breaths per minute but the exact approach
does vary from centre to centre. This strategy prevents any further
lung damage secondary to barotrauma but arrests the atelectasis,
which might follow acute withdrawal of respiratory support and
enhances clearance of secretions.
The point in an individual baby’s course at which ECMO should
be considered is debatable. A variety of physiological and clinical
parameters have been used. Over time, oxygenation index (OI) of
greater than 40 has probably become the most widely employed,
where
OI =(FiO2) * (mean airway pressure cm H2O) * 100 / PaO2 mm
Hg.
Although the absolute number of babies who reach this level of
severity is never likely to be large, the potential benefits of ECMO
may be extremely high. However, ECMO is very invasive and
because it is so labour intensive, it is expensive. Hence there is a
need for rigorous evaluation of its advantages and disadvantages
to guide practice.
O B J E C T I V E S
To determine whether ECMO used for neonatal infants with se-
vere respiratory failure is clinically effective (especially in terms of
mortality and childhood disability) compared to a policy of con-
ventional ventilatory support. The two approaches will also be as-
sessed in terms of their relative resource use and cost-effectiveness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised trials comparing neonatal ECMO to conventional
ventilatory support
Types of participants
All infants with severe but potentially reversible respiratory failure,
aged less than 28 days, with gestation at birth of 34 weeks or
more were included. Trials relying on a range of physiological
parameters to identify infants who had “severe but potentially
reversible respiratory failure” (e.g. PaO2<40mmHgor pH<7.15
for two hours) as well as those using the criterion of an oxygenation
index of > 40 to select patients were all included.
Secondary analyses of the primary outcomes (see below) are based
on those with and without a primary diagnosis of congenital di-
aphragmatic hernia, and by severity (oxygenation index between
40 to 60, and over 60)
Types of interventions
Extracorporeal membrane oxygenation versus conventional venti-
latory management
Types of outcome measures
Outcome measures focused on mortality, disability and use of
health service resources. Specifically, the primary outcomes are
death, death or severe disability, death or disability, severe disabil-
ity, and any disability, all considered at discharge from hospital,
at one year, at four years, at seven years, and to the end of data
collection.
Other outcomes include impairment (with or without disability)
at one year of age, readmission to hospital in the first year, need for
supplemental oxygen at one year of age, tube feeding at one year,
weight < the 3rd percentile at one year of age, head circumference
< the 3rd percentile at one year of age, head circumference > the
97th percentile at one year of age, visual problems at one year of
age, hearing problems at one year of age, on anticonvulsants at
one year of age, changes in neuromotor tone at one year of age,
asymmetrical neuromotor signs at one year of age, abnormal ax-
ial tone at one year of age, abnormal movements at one year of
age, motor developmental quotient < 50 at one year of age, motor
developmental quotient < 70 at one year of age, overall develop-
mental quotient < 70 at one year of age, professional support for
special needs at four years of age. Other outcomes at seven year
include information on any disability and severe disability in the
cognitive, neuromotor, general health, behaviour, visual and hear-
ing domains.
Outcomes indicating use of resources indicating levels of inten-
siveness, and therefore cost, of care are: days on ECMO, days on
oxygen > 90%, days on ventilator, days on supplemental oxygen
before first discharge home, and days in hospital before first dis-
charge home. These categories are not mutually exclusive. Further
indication of increased or reduced health and other care resource
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use is given by the readmission to hospital one year of age; pro-
fessional support for special needs up to four years; and days in
hospital, outpatient hospital visits, and visits by family doctors,
health visitor and other professionals, up to seven years.
Incremental cost per additional survivor and per additional sur-
vivor without disability at one, four and seven years of age are also
reported in local currency values, without summary statistics.
Other outcomes not considered in the review protocol but pro-
vided by authors have been given within the Included Studies Ta-
ble.
Search methods for identification of studies
The Cochrane Central Register of Controlled Trials (The
Cochrane Library, Issue 4, 2007) and the Cochrane Neona-
tal Group Specialised Register were searched using keywords
ECMO, extra corporeal membrane oxygenation, extracorporeal
membrane oxygenation, extra-corporeal membrane oxygenation,
and neonat*. MEDLINE was also searched. Searches covered the
period 1974 to 2007.
Data collection and analysis
Trials under consideration were evaluated for their methodolog-
ical quality (in terms of concealment of allocation, masking of
intervention (where appropriate), completeness of follow-up, and
masking of outcome assessment (where appropriate)), and appro-
priateness for inclusion in the review, by two authors indepen-
dently, without consideration of their results.
Trial data were extracted by two authors independently
Further information was sought from the authors of the trials, as
appropriate.
Analysis was by intention to treat, using Review Manager
(RevMan) software. For dichotomous data, summary relative risks
were calculated using a fixed effects model providing there was
no significant heterogeneity. For continuous data, weighted mean
differences were calculated. 95% confidence intervals were used.
Trials that included economic analysis were noted, and associated
publication of economic findings referenced. Critical abstracts of
economic evaluations of ECMO are available in the NHS eco-
nomic evaluation database, which is also included in theCochrane
Library. In this review, data about key items of resource use and
patient based costs are reported. Where studies meet BMJ criteria
for economic evaluation (Drummond 1996) and also report mea-
sures of incremental cost-effectiveness, this is also reported.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
The original review identified four trials, all of which met the
entry criteria. No further trials were identified in 2006 search but
four new papers were considered. One paper (Schaub 2002) was
the report in German of the UK ECMO trial (see below). Three
other papers were reports of the follow-up from the UK ECMO
trial, including the seven year follow-up (McNally 2006) and two
economic evaluations - at four years (Petrou 2004), and at seven
years (Petrou 2006).
Three of the four trials were carried out in the USA (Boston
1989; Michigan 1985; and Syracuse 1992 ), and one in the UK
(UK 1996) . All four trials recruited clinically similar groups of
term or near-term newborn babies with severe respiratory distress,
although two (Boston, Syracuse) excluded infants with congenital
diaphragmatic hernias. In two of the trials (Syracuse 1992; and
UK 1996), transfer for ECMO usually implied transport over a
considerable distance, whereas in Michigan all the babies were
cared for in the same hospital, and in Boston the ECMO centre
was in the same city.
One study was associated with a full economic evaluation, re-
ported separately (Roberts 1998; Petrou 2004; Petrou 2006). The
related economic studies meet criteria for inclusion in the NHS
Economic Evaluation Database (NHSEED). The first report of
the economic evaluation of the UK trial (Roberts 1998) is updated
by Petrou 2006. Hyperlinks for the NHSEED critical abstracts of
these papers are:
http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?
ID=21998008232 (Roberts 1998)
http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?
ID=22004000682 (Petrou 2004).
http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=
22006006380 (Petrou 2006)
Risk of bias in included studies
Data from the Syracuse trial have only been published as two
conference abstracts. Although the investigators kindly provided
copies of the slides which they used at the respective conferences
and updated the information on the Bayley scores, the data were
not always sufficient to be able to fully assess the methodological
quality of the trial.
All the trials except the UK trial had very small numbers of pa-
tients. Three of the trials (Boston,Michigan andUK)were stopped
early for effectiveness on the advice of the relevant Data Monitor-
ing Committee, in accordance with pre-specified stopping rules
in their trial protocols. Nevertheless, as early stopping is often as-
sociated with a random high, it is possible that the reported effect
sizes may be exaggerations of the true treatment effect.
Two of the trials (Syracuse and UK) used conventional randomi-
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sation methods with low potential for selection bias at trial entry.
They also used an intention to treat analysis based on patients in
the groups to which they were randomised, and with virtually no
loss to follow-up. Although the treatments could not be masked
after randomisation, the outcome measures such as death were
unlikely to be subject to observer bias, and the assessors at paedi-
atric follow-up in the UK trial were kept unaware of the treatment
allocation.
There were more problems about methodological quality in the
other two trials which used less usual designs. Both employed a
Zelen design (Zelen 1979) in which informed consent to treat-
ment was requested after randomisation and only in the ECMO
arm. This method has high potential for selection biases before
and after trial entry if the recruiting clinician, on seeing which
treatment has been randomly allocated to a particular patient,
then does not ask that patient /parent for consent to the (known)
treatment and/or to the follow-up; parents may also decide not to
consent to a particular treatment, and/or to enter their baby into
the trial and/or to give permission for follow-up. The potential for
bias arises because these decisions are made in knowledge of the
allocated treatment and may therefore be differentially affected by
that knowledge. This may be even more of a problem if, as in
these ECMO trials, a single consent design is used, as one group
may not have the opportunity to refuse. The trial reports do not
provide sufficient information to be able to assess the extent of
these biases (although the Boston trial states that there were no
post-randomisation exclusions).
They also used ’response-adaptive’ designs. In the Boston trial, this
led to a decision to halt randomisation after the fourth death in
either trial group. (There was also subsequently a non-randomised
phase of this trial, but data from that phase have not been used in
this review). In the Michigan trial, the adaptive design used the
’play the winner’ strategy in which the first patient was given an
equal chance of randomisation to either trial arm, but subsequent
allocations were based on the results for the previous allocation,
with a higher probability of allocation to the treatment doing bet-
ter at the time. This has led to a major imbalance in the numbers
of infants in each trial arm (only one in the conventional manage-
ment arm). These unusual designs have led to difficulties in the
interpretation of their results.
All four studies reported one or more of the defined resource use
outcomes, but the three American studies provided this informa-
tion for survivors only. The economic evaluations reported from
the UK study are from the health services viewpoint, taking ac-
count of both hospital and community care costs. The resource use
cost analysis is most relevant to the UKNHS, where the economic
analysis was conducted. Full economic analyses of cost effective-
ness were conducted at one, four and seven years, and sensitivity
and uncertainty analysis was also included.
Effects of interventions
Very few of the trials provided information about all the planned
outcomes, and only the UK and Syracuse trials had any follow-up
information. Therefore, very few of the comparisons show data for
all the outcomes, either overall, or in the pre-specified subgroups.
Mortality
Death before discharge home (or to the end of data collection)
were the only outcomes reported for all four trials. For death before
discharge home, each of the four trials showed a strong benefit of
ECMO, but as the three US trials were all very small, the size of
effect (typical RR 0.44) was overwhelmingly determined by the
UK trial and the 95% CI was very tight (0.31 to 0.61), a highly
statistically significant benefit (p < 0.00001) (Outcome 1.1). This
can also be expressed as a difference in rates of -0.32 (95% CI -
0.44 to -0.20), implying only three babies need to be treated with
ECMO rather than conventional ventilation to prevent one death.
The situation was similar for deaths to the end of data collection
(typical RR 0.51, 95% CI 0.37 to 0.70; p = 0.00003) (Outcome
1.3), although there were some later deaths in the ECMO arm
(from the trials with follow up).
The majority of patients in these trials did not have congenital
diaphragmatic hernia as the primary diagnosis either because this
was an exclusion criterion (Boston and Syracuse) or because the
numbers with this primary diagnosis were relatively small (1/12
in the Michigan trial and 35/185 in the UK trial). The risk of
death by discharge for babies without this diagnosis was reduced
even more (typical RR 0.33, 95% CI 0.21 to 0.53; p < 0.00001)
(Outcome 2.1). The results were similar for deaths to the end
of data collection (typical RR 0.41, 95% CI 0.27 to 0.63; p =
0.00004) (Outcome 2.3). Even for the 35 babies in the UK trial
with a primary diagnosis of congenital diaphragmatic hernia, the
risk of death at four years was reduced (RR 0.84, 95% CI 0.67
to 1.05; p = 0.08) but only five infants survived to discharge, and
only three children survived to seven years of age, all in the ECMO
arm (17/17 of the infants in the conventional management arm
died before discharge).
Death or disability
Only the UK trial provided information about death or disability
at one, four and seven years. This again showed an overall benefit
of ECMO at one year (RR 0.56, 95% CI 0.40 to 0.78; p = 0.006)
(Outcome 1.7), and at four, and seven years (RR 0.62, 95% CI
0.45 to 0.86; p = 0.004) (Outcomes 1.26, 1.28). The benefit was
even more marked in the subgroup of children who did not have
a primary diagnosis of congenital diaphragmatic hernia at trial
entry (RR at one year 0.45, 95% CI 0.28 to 0.72; p = 0.009),
and at four and seven years (RR 0.49, 95% CI 0.31 to 0.77; p =
0.002). The trend towards benefit for the children with congenital
diaphragmatic hernia at trial entry was much less marked (RR at
one year 0.78, 95%CI 0.61 to 1.00; p = 0.05) (Outcome 2.6), and
at four years (RR 0.89, 95% CI 0.75 to 1.05; p = 0.16) (Outcome
2.7), with only two children alive and not severely disabled, both
in the ECMO arm.
The Oxygenation Index at trial entry was used as a measure of
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severity. The effect of a policy of ECMO by four years of age was
more marked in the less severe stratum of OI 40 - 60 (death or
severe disability at four years RR 0.52, 95% CI 0.31 to 0.85; p =
0.010) than the more severe stratum of OI > 60 (death or severe
disability at four years RR 0.76, 95% CI 0.52 to 1.12; p = 0.16)
although the trend is in the same direction.
Disability and impairment
Data from the UK trial at one year showed no clear trend in re-
lation to the risk of disability or impairment. Assessment of chil-
dren at one year is difficult to interpret and hence developmental
assessments are likely to have lacked precision.
At four years much more detailed information was available. Five
children were lost to follow-up (three in the conventional man-
agement group). Of the 60 randomised to ECMO and assessed
at four years, 12 appeared normal and 18 had signs of impair-
ment without disability. The remaining 30 had signs of disability
(three severe). In the conventional arm 35 children were assessed,
of whom four appeared normal with nine having signs of impair-
ment without disability. The other 22 children in this group were
disabled but none were considered severe. The data did not sug-
gest that an increased risk of particular types of adverse neurode-
velopmental outcome (e.g. hemiplegia) was associated with either
group.
Four children were lost to follow-up between the ages of four and
seven. By seven years, extra information was available, particularly
about cognition and behaviour.
Of the 56 randomised to ECMO and assessed at seven years,
10 appeared normal and 21 had signs of impairment without
disability. The remaining 25 had signs of disability (three severe).
In the conventional arm 34 children were assessed, of whom two
appeared normal with 15 having signs of impairment without
disability. The other 17 children in this group were disabled but
none were considered severe.
Use of health services
Measures of resource use were analysed as continuous variables. In
the initial hospitalisation, more resources were used in the ECMO
arm, including ECMO days, days on ventilator, days on supple-
mentary oxygen, days of standard neonatal care, days in hospital
and transport. The only exception was in the case of days on more
than 90% oxygen, where conventionally managed babies had a
mean of 3.56 days compared to 1.48 days for the ECMO arm.
Differences in resource use at this stage are partly explained by
higher early mortality in the conventional management arm.
In the period fromdischarge from initial hospitalisationuntil seven
year follow-up, there was consistently higher use of health care
resources in the ECMOarm, but this is largely because of increased
survival in this group.
Costs and cost effectiveness
The incremental cost effectiveness ratio (ICER) of ECMO over
seven years was estimated to be £13,385 (95%CI 7,967 to 27,672)
per life year gained, and to be £23,566 ( 95%CI 9,571 to 107,632)
per disability free life year gained. The sensitivity analysis for cost
effectiveness in subgroups showed that for children diagnosedwith
no diaphragmatic hernia, the incremental cost effectiveness per
life year gained was £8,082, and per disability free life year gained,
£14,124. The equivalent ICERs for children with diaphragmatic
hernia were £42,080 and £79,013. The purchasing power parity
between £GB to US$ in 2003 was £0.627 GB=$1US (OECD
2006).
D I S C U S S I O N
There was clear benefit for the ECMO policy in terms of reduc-
ing mortality and, although there were some later deaths in the
ECMO arm, the balance of benefits remains strongly in favour of
the ECMO policy for this outcome. Although there was a non-
statistically significant tendency towards more disability in the
ECMO group at one year, this was no longer the case by four or
seven years of age in theUK trial. There was also an important ben-
efit of ECMO when considering the composite outcome of death
OR severe disability at one, four and seven years of age. Fuller
details of other outcomes from the UK trial shown in the accom-
panying figures do not alter these conclusions, although numbers
of children with any one specific adverse outcome are small.
The diagnosis of severe but potentially reversible respiratory fail-
ure is not straightforward. Over the time that ECMO has been
available a variety of indices have been used in this role. All are
intended to identify babies with a high probability of death from
continued conventional therapy. The results of this review would
indicate that they achieve this aim. The various measures used to
identify suitable infants have not been compared but this seems
unnecessary given the randomised nature of the subsequent stud-
ies.
The invasive nature of ECMOhas been the cause ofmuch concern.
The potential for acute problems related to the ECMO circuit
and the inevitable disruption to the cerebral circulation led many
to make the broad assumption that there was an inherent risk
attached to the use of ECMO which would inevitably result in
increasedmorbidity. These concerns have not been born out. Since
the risks are undeniable it would appear that the damaging effect
of prolonged exposure to aggressive conventional therapy as used
in the 1990s are even greater. It is important to note that only
a minority of all recruited infants could be considered normal
survivors at seven years. Although ECMO has been considered as
a single entity in this comparison there was significant use of the
veno venous technique in the UK study whilst this was not the
case in earlier trials.
The majority of patients in these trials did not have congeni-
tal diaphragmatic hernia as the primary diagnosis either because
this was an exclusion criterion (Boston and Syracuse) or because
the numbers with this primary diagnosis were small (1/12 in the
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Michigan trial and 35/185 in the UK trial). Although the balance
of benefit was still marginally in favour of the ECMO policy (17/
17 of the infants in the conventional management arm died before
discharge), by the age of seven years, 16/18 of those in the ECMO
arm had also died or were severely disabled.
There was no evidence that the severity of illness as judged by an
OI of 40 to 60 or over 60 affected the benefit of the ECMOpolicy.
Although there is a clear benefit for the ECMO policy, overall
nearly half of the children had died or were severely disabled at four
years of age, reflecting the severity of their underlying conditions.
Nevertheless, based on the economic analysis from the UK trial,
the ECMO policy is not only clinically effective but also as cost-
effective as other intensive care technologies in common use.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A policy of using ECMO in mature infants with severe but po-
tentially reversible respiratory failure would result in significantly
improved survival without any increased risk of severe disability
amongst survivors. A variety of indices can be used to define such
infants but the use of an oxygenation index of 40 seems the most
straightforward.
The situation for babies with diaphragmatic hernia is less clear
since, despite their common underlying anomaly, they do not rep-
resent a homogeneous group. It would appear that ECMO offers
short term benefits but the overall effect of employing ECMO
in this group is not clear. In the absence of a definitive study the
use of ECMO can only be recommended on clinical grounds i.e.
where it can be used to stabilise a baby thought to be potentially
viable but failing more conventional support.
Cost effectiveness is sensitive to the organisation of health care
for ECMO and intensive neonatal care. Lower cot occupancy and
higher staff to cot ratios increase costs, as do long travel times and
distances.
Implications for research
Further studies are needed to refine ECMO techniques in an at-
tempt to reduce both short term risks (such as circuit failure) and
the damage that might result from physiological disruption. A for-
mal comparison of veno venous and veno arterial ECMO seems
particularly important in this regard.
The identification of suitable infants also merits further consider-
ation. At present infants are referred for ECMO when other ther-
apies have failed and the baby is continuing to deteriorate. Out-
comes might be improved by introducing ECMO earlier, i.e. as
soon as all other therapies have failed.
The longer term effects of neonatal ECMO (e.g. during later child-
hood, adolescence and adult life) remain unclear. Studies to ad-
dress these issues are clearly important if infants are going to con-
tinue to be offered this form of life support.
The correct approach to themanagement of infants with diaphrag-
matic hernia is not known. Large randomised studies, with long
term follow-up, are needed in order to establish both the best ap-
proach to acute management and the extent to which “normal
survival” is achievable with our present treatment options. There
is some uncertainty about what constitutes “present treatment op-
tions” and establishing the test arms would clearly be the first step
in developing such a study.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boston 1989
Methods Adaptive design with single consent Zelen randomisation. No post- randomisation exclusions. Randomi-
sation in balanced blocks of size 4 and planned to cease after 4th death in either group. Phase II was non
-randomised enrolment in group with <4 deaths until 4th death in that group or or number of survivors
significantly larger than number of survivors in arm discontinued first
Participants 19 infants with severe persistent pulmonary hypertension and respiratory failure. Birthweight >= 2.5 kg,
gestational age >= 38 weeks, normal cranial ultrasound, severe hypoxemia, 80% predicted mortality based
on PaO2/PAO2 <=0.15 on 2 occasions > 30 mins apart between 12 and 72 hours after birth. Exclusions:
congenital diaphragmatic hernia, heart disease
Interventions Extra Corporeal Membrane Oxygenation (venoarterial) usually involving transport to a multidisciplinary
intensive care unit (within Boston).
Conventional treatment remained on optimal ventilatory support in initial neonatal intensive care unit
Outcomes Death, duration of ventilation and of supplemental oxygen, intracranial haemorrhage, complications of
ECMO
Notes Methodological quality
Masking of intervention (not possible) Completeness of follow-up (yes, until discharge) Masking of
outcome assessment (mortality outcome so masking not appropriate)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Michigan 1985
Methods Adaptive design with single consent Zelen randomisation.
’Play the winner’ - 1st patient equal chance of randomisation to either arm, but subsequent assignments
based on results for previous patients - higher probability for treatment doing better
Participants 12 infants with newborn respiratory failure; > 2kg birthweight; any of following:
1 acute deterioration PaO2<40 mmHg of pH<7.15 for 2 hours
2. Unresponsive- ness (2 of 3 indication for 3 hours - PaO2<55, pH<7.4 or hypotension
3. barotrauma
4. congenital diaphragmatic hernia
5 80%+ mortality index at 24 hours
Exclusions: intracranial haemorrhage grade II or more;
> 7 days; incompatible with normal quality life
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Michigan 1985 (Continued)
Interventions Single centre for both treatments. ExtraCorporealMembraneOxygenation (venoarterial if signs of haemo-
dynamic instability, otherwise veno-venous).
Conventional treatment remained on optimal ventilatory support
Outcomes Death, duration of ventilation and of hospital stay, intracranial haemorrhage, complications of ECMO
some follow up
Notes Methodological quality
Masking of intervention (not possible) Completeness of follow-up (yes, until discharge) Masking of
outcome assessment (mortality outcome so masking not appropriate)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Syracuse 1992
Methods Assigned randomly (no other details).
Participants 28 infants with respiratory failure - oxygenation index >40 for 4 hours; >35 weeks; >= 2 kg; 10 days;
Exclusions: intraventricular haemorrhage, structural heart disease, congenital diaphragmatic hernia; severe
congenital anomaly
Interventions Single centre for conventional treatment.
Transport for Extra Corporeal Membrane Oxygenation (venoarterial) in one of 3 centres.
Conventional treatment remained on optimal ventilatory support
Outcomes Death, duration of ventilation, of supplemental oxygen, and of hospital stay, intracranial haemorrhage,
complications of ECMO. Follow up to 2 years - neurological abnormality, Bayley scores
Notes Methodological quality
Masking of intervention (not possible) Completeness of follow-up (yes, until discharge, and good at
follow up) Masking of outcome assessment (masking not appropriate for mortality outcome; not clear if
paediatric assessor masked)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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UK 1996
Methods Central telephone randomisation with minimisation on primary diagnosis, severity, and referral hospital
and ECMO centre
Participants 185 infants with severe respiratory failure (oxygenation index >40); > 2kg birthweight; >35 weeks gesta-
tion;
<10 days high pressure ventilation; < 28 days old; no contraindiction for ECMO (ventricular haemorrhage,
irreversible cardiopulmonary disease, asystole, necrotising enterocolitis); no major congenital anomaly
Interventions Transport for Extra Corporeal Membrane Oxygenation (venoarterial) in one of 5 centres.
Conventional care in centre accustomed to providing optimal ventilatory support
Outcomes Death, duration of ventilation, of supplemental oxygen, and of hospital stay, intracranial haemorrhage,
complications of ECMO. Follow up to 1 and 4 years - respiratory, growth, vision, hearing, neuromotor/
neurological abnormality, Griffith scores; disability and impairment; health service use and cost effective-
ness. Follow-up at 7 years, - assessments of respiratory, growth, vision, hearing, neuromotor/neurological
abnormality, disability and impairment, cognition (British Ability Scales), memory and behaviour , health
service use and cost effectiveness
Notes Methodological quality
Masking of intervention (not possible)Completeness of follow-up (yes, until discharge, and good at follow-
up) Masking of outcome assessment (masking not appropriate for mortality outcome, and paediatric
assessment was masked)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Schaub 2002 This is just a report in German of the UK ECMO trial
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D A T A A N D A N A L Y S E S
Comparison 1. All eligible infants
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death before discharge home 4 244 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.31, 0.61]
2 Death in the first year of life 2 213 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.37, 0.73]
3 Death at any time to the end of
data collection
4 244 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.37, 0.70]
4 Severe disability in survivors at
one year of age
1 99 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.04, 9.26]
5 Disability (severe and not severe)
in survivors at one year of age
2 119 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.62, 3.51]
6 Impairment (with or without
disability) in survivors at one
year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Death or severe disability at one
year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Readmission to hospital in
survivors in first year
2 119 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.46, 1.01]
9 On supplemental oxygen in
survivors at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10 Tube feeding in survivors at
one year
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
11 Weight < 3rd centile in
survivors at one year of age
2 119 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.52, 6.20]
12 Head circumference < 3rd
centile in survivors at one year
of age
2 119 Risk Ratio (M-H, Fixed, 95% CI) 2.93 [0.53, 16.11]
13 Head circumference > 97th in
survivors centile at one year of
age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
14 Vision problems in survivors at
one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
15 Hearing problems in survivors
at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
16 On anticonvulsants in survivors
at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
17 Neuromotor tone changes in
survivors at one year
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
18 Asymmetrical neuromotor
signs in survivors at one year of
age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
19 Abnormal axial tone in
survivors at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
20 Abnormal movements in
survivors at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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21 Motor Developmental
Quotient less than 50 in
survivors at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
22 Motor Developmental
Quotient less than 70 in
survivors at one year of age
2 119 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.43, 3.93]
23 Overall Developmental
Quotient less than 70 in
survivors at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
24 Severe disability in survivors at
4 years of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
25 Any disability in survivors at 4
years of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
26 Death or severe disability at 4
years of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
27 Professional support for special
needs in survivors at 4 years of
age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
28 Death or severe disability at 7
years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
29 Death by 7 years 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
30 Severe disability in survivors at
7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
31 Any disability in survivors at 7
years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
32 Any cognitive disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
33 Severe cognitive disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
34 Any neuromotor disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
35 Severe neuromotor disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
36 Any general health disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
37 Severe general health disability
in survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
38 Any behavioural disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
39 Severe behavioural disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
40 Any visual disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
41 Severe visual disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
42 Any hearing disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
43 Severe hearing disability in
survivors at 7 years
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
44 Days on ECMO 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
45 Days on > 90% oxygen 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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46 Days on ventilator 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
47 Days on supplementary oxygen
at any concentration
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
48 Days on standard neonatal care 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
49 Days in hospital (initial
admission)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
50 Number of ambulance journeys 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
51 Days in hospital (all
re-admissions up to 7 years)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
52 Number of hospital outpatient
visits up to 7 years
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
53 Number of family doctor visits
up to 7 years
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
54 Number of health visitor visits
up to 7 years
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
55 Number of visits by other
professionals up to 7 years
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
56 Total health service costs (£GB
2003 prices)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Infants without congenital diaphragmatic hernia as principal diagnosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death before discharge home 4 208 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.21, 0.53]
2 Death in the first year of life 2 178 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.28, 0.68]
3 Death at any time to the end of
data collection
4 208 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.27, 0.63]
4 Severe disability in survivors at
one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Disability (severe and not severe)
in survivors at one year of age
2 115 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.50, 3.07]
6 Death or severe disability at one
year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Death or severe disability at 4
years of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 3. Infants with congenital diaphragmatic hernia as principal diagnosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death before discharge home 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Death in the first year of life 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Death at any time to the end of
data collection
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Death or severe disability at one
year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Death or severe disability at 4
years of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Infants with oxygenation index 40-60 at trial entry
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe disability in survivors at
one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Disability (severe and not severe)
in survivors at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Death or severe disability at 4
years of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 5. Infants with oxygenation index > 60 at trial entry
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Severe disability in survivors at
one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Disability (severe and not severe)
in survivors at one year of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Death or severe disability at 4
years of age
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 All eligible infants, Outcome 1 Death before discharge home.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 1 Death before discharge home
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boston 1989 0/9 4/10 6.3 % 0.12 [ 0.01, 2.00 ]
Michigan 1985 0/11 1/1 3.8 % 0.06 [ 0.00, 0.94 ]
Syracuse 1992 1/15 6/13 9.5 % 0.14 [ 0.02, 1.05 ]
UK 1996 28/93 54/92 80.3 % 0.51 [ 0.36, 0.73 ]
Total (95% CI) 128 116 100.0 % 0.44 [ 0.31, 0.61 ]
Total events: 29 (ECMO), 65 (Conventional)
Heterogeneity: Chi2 = 4.84, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 4.76 (P < 0.00001)
0.005 0.1 1 10 200
Favours treatment Favours control
Analysis 1.2. Comparison 1 All eligible infants, Outcome 2 Death in the first year of life.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 2 Death in the first year of life
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Syracuse 1992 2/15 6/13 10.6 % 0.29 [ 0.07, 1.19 ]
UK 1996 30/93 54/92 89.4 % 0.55 [ 0.39, 0.77 ]
Total (95% CI) 108 105 100.0 % 0.52 [ 0.37, 0.73 ]
Total events: 32 (ECMO), 60 (Conventional)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.84 (P = 0.00012)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
16Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 All eligible infants, Outcome 3 Death at any time to the end of data collection.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 3 Death at any time to the end of data collection
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boston 1989 0/9 4/10 6.3 % 0.12 [ 0.01, 2.00 ]
Michigan 1985 3/11 1/1 3.8 % 0.39 [ 0.12, 1.28 ]
Syracuse 1992 2/15 6/13 9.5 % 0.29 [ 0.07, 1.19 ]
UK 1996 31/93 54/92 80.3 % 0.57 [ 0.41, 0.79 ]
Total (95% CI) 128 116 100.0 % 0.51 [ 0.37, 0.70 ]
Total events: 36 (ECMO), 65 (Conventional)
Heterogeneity: Chi2 = 2.24, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 4.21 (P = 0.000026)
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 1.4. Comparison 1 All eligible infants, Outcome 4 Severe disability in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 4 Severe disability in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 1/62 1/37 100.0 % 0.60 [ 0.04, 9.26 ]
Total (95% CI) 62 37 100.0 % 0.60 [ 0.04, 9.26 ]
Total events: 1 (ECMO), 1 (Conventional)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
0.05 0.2 1 5 20
Favours treatment Favours control
Analysis 1.5. Comparison 1 All eligible infants, Outcome 5 Disability (severe and not severe) in survivors at
one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 5 Disability (severe and not severe) in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Syracuse 1992 2/13 1/7 17.2 % 1.08 [ 0.12, 9.89 ]
UK 1996 13/62 5/37 82.8 % 1.55 [ 0.60, 4.00 ]
Total (95% CI) 75 44 100.0 % 1.47 [ 0.62, 3.51 ]
Total events: 15 (ECMO), 6 (Conventional)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.6. Comparison 1 All eligible infants, Outcome 6 Impairment (with or without disability) in
survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 6 Impairment (with or without disability) in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 17/62 10/37 1.01 [ 0.52, 1.98 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 1.7. Comparison 1 All eligible infants, Outcome 7 Death or severe disability at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 7 Death or severe disability at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 31/93 55/92 0.56 [ 0.40, 0.78 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 1.8. Comparison 1 All eligible infants, Outcome 8 Readmission to hospital in survivors in first year.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 8 Readmission to hospital in survivors in first year
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Syracuse 1992 6/13 5/7 21.5 % 0.65 [ 0.30, 1.37 ]
UK 1996 22/62 19/37 78.5 % 0.69 [ 0.44, 1.09 ]
Total (95% CI) 75 44 100.0 % 0.68 [ 0.46, 1.01 ]
Total events: 28 (ECMO), 24 (Conventional)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 1.9. Comparison 1 All eligible infants, Outcome 9 On supplemental oxygen in survivors at one year
of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 9 On supplemental oxygen in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 3/62 2/37 0.90 [ 0.16, 5.11 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.10. Comparison 1 All eligible infants, Outcome 10 Tube feeding in survivors at one year.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 10 Tube feeding in survivors at one year
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 3/62 1/37 1.79 [ 0.19, 16.59 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.11. Comparison 1 All eligible infants, Outcome 11 Weight < 3rd centile in survivors at one year
of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 11 Weight < 3rd centile in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Syracuse 1992 0/13 0/7 Not estimable
UK 1996 9/62 3/37 100.0 % 1.79 [ 0.52, 6.20 ]
Total (95% CI) 75 44 100.0 % 1.79 [ 0.52, 6.20 ]
Total events: 9 (ECMO), 3 (Conventional)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
0.2 0.5 1 2 5
Favours treatment Favours control
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Analysis 1.12. Comparison 1 All eligible infants, Outcome 12 Head circumference < 3rd centile in survivors
at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 12 Head circumference < 3rd centile in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Syracuse 1992 3/13 0/7 33.7 % 4.00 [ 0.24, 67.99 ]
UK 1996 4/62 1/37 66.3 % 2.39 [ 0.28, 20.56 ]
Total (95% CI) 75 44 100.0 % 2.93 [ 0.53, 16.11 ]
Total events: 7 (ECMO), 1 (Conventional)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
0.02 0.1 1 10 50
Favours treatment Favours control
Analysis 1.13. Comparison 1 All eligible infants, Outcome 13 Head circumference > 97th in survivors
centile at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 13 Head circumference > 97th in survivors centile at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 5/62 2/37 1.49 [ 0.30, 7.30 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.14. Comparison 1 All eligible infants, Outcome 14 Vision problems in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 14 Vision problems in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 9/62 2/37 2.69 [ 0.61, 11.76 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.15. Comparison 1 All eligible infants, Outcome 15 Hearing problems in survivors at one year of
age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 15 Hearing problems in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 12/62 12/37 0.60 [ 0.30, 1.19 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 1.16. Comparison 1 All eligible infants, Outcome 16 On anticonvulsants in survivors at one year of
age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 16 On anticonvulsants in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 2/62 0/37 3.02 [ 0.15, 61.16 ]
0.02 0.1 1 10 50
Favours treatment Favours control
Analysis 1.17. Comparison 1 All eligible infants, Outcome 17 Neuromotor tone changes in survivors at one
year.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 17 Neuromotor tone changes in survivors at one year
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 10/62 5/37 1.19 [ 0.44, 3.22 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 1.18. Comparison 1 All eligible infants, Outcome 18 Asymmetrical neuromotor signs in survivors
at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 18 Asymmetrical neuromotor signs in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 12/62 3/37 2.39 [ 0.72, 7.91 ]
0.2 0.5 1 2 5
Favours treatment Favours control
Analysis 1.19. Comparison 1 All eligible infants, Outcome 19 Abnormal axial tone in survivors at one year
of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 19 Abnormal axial tone in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 7/62 3/37 1.39 [ 0.38, 5.06 ]
0.2 0.5 1 2 5
Favours treatment Favours control
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Analysis 1.20. Comparison 1 All eligible infants, Outcome 20 Abnormal movements in survivors at one year
of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 20 Abnormal movements in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boston 1989 2/62 0/37 3.02 [ 0.15, 61.16 ]
0.02 0.1 1 10 50
Favours treatment Favours control
Analysis 1.21. Comparison 1 All eligible infants, Outcome 21 Motor Developmental Quotient less than 50 in
survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 21 Motor Developmental Quotient less than 50 in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 2/62 2/37 0.60 [ 0.09, 4.06 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.22. Comparison 1 All eligible infants, Outcome 22 Motor Developmental Quotient less than 70 in
survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 22 Motor Developmental Quotient less than 70 in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Syracuse 1992 4/13 1/7 25.7 % 2.15 [ 0.29, 15.75 ]
UK 1996 5/62 3/37 74.3 % 0.99 [ 0.25, 3.92 ]
Total (95% CI) 75 44 100.0 % 1.29 [ 0.43, 3.93 ]
Total events: 9 (ECMO), 4 (Conventional)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.23. Comparison 1 All eligible infants, Outcome 23 Overall Developmental Quotient less than 70
in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 23 Overall Developmental Quotient less than 70 in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 2/62 2/37 0.60 [ 0.09, 4.06 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.24. Comparison 1 All eligible infants, Outcome 24 Severe disability in survivors at 4 years of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 24 Severe disability in survivors at 4 years of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 3/60 0/35 4.13 [ 0.22, 77.71 ]
0.02 0.1 1 10 50
Favours treatment Favours control
Analysis 1.25. Comparison 1 All eligible infants, Outcome 25 Any disability in survivors at 4 years of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 25 Any disability in survivors at 4 years of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 30/60 22/35 0.80 [ 0.56, 1.14 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 1.26. Comparison 1 All eligible infants, Outcome 26 Death or severe disability at 4 years of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 26 Death or severe disability at 4 years of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 34/93 54/92 0.62 [ 0.45, 0.86 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 1.27. Comparison 1 All eligible infants, Outcome 27 Professional support for special needs in
survivors at 4 years of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 27 Professional support for special needs in survivors at 4 years of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 16/60 10/35 0.93 [ 0.48, 1.83 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 1.28. Comparison 1 All eligible infants, Outcome 28 Death or severe disability at 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 28 Death or severe disability at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 34/93 54/92 0.62 [ 0.45, 0.86 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 1.29. Comparison 1 All eligible infants, Outcome 29 Death by 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 29 Death by 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 31/93 54/92 0.57 [ 0.41, 0.79 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 1.30. Comparison 1 All eligible infants, Outcome 30 Severe disability in survivors at 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 30 Severe disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 3/56 0/34 4.30 [ 0.23, 80.75 ]
0.02 0.1 1 10 50
Favours treatment Favours control
Analysis 1.31. Comparison 1 All eligible infants, Outcome 31 Any disability in survivors at 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 31 Any disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 25/56 17/34 0.89 [ 0.57, 1.39 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 1.32. Comparison 1 All eligible infants, Outcome 32 Any cognitive disability in survivors at 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 32 Any cognitive disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 13/56 8/34 0.99 [ 0.46, 2.13 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 1.33. Comparison 1 All eligible infants, Outcome 33 Severe cognitive disability in survivors at 7
years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 33 Severe cognitive disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 3/56 0/34 4.30 [ 0.23, 80.75 ]
0.02 0.1 1 10 50
Favours treatment Favours control
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Analysis 1.34. Comparison 1 All eligible infants, Outcome 34 Any neuromotor disability in survivors at 7
years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 34 Any neuromotor disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 9/56 5/34 1.09 [ 0.40, 2.99 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 1.35. Comparison 1 All eligible infants, Outcome 35 Severe neuromotor disability in survivors at 7
years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 35 Severe neuromotor disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 1/56 0/34 1.84 [ 0.08, 43.98 ]
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.36. Comparison 1 All eligible infants, Outcome 36 Any general health disability in survivors at 7
years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 36 Any general health disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 2/56 0/34 3.07 [ 0.15, 62.10 ]
0.02 0.1 1 10 50
Favours treatment Favours control
Analysis 1.37. Comparison 1 All eligible infants, Outcome 37 Severe general health disability in survivors at
7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 37 Severe general health disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 1/56 0/34 1.84 [ 0.08, 43.98 ]
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.38. Comparison 1 All eligible infants, Outcome 38 Any behavioural disability in survivors at 7
years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 38 Any behavioural disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 12/56 12/34 0.61 [ 0.31, 1.20 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.39. Comparison 1 All eligible infants, Outcome 39 Severe behavioural disability in survivors at 7
years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 39 Severe behavioural disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 1/56 0/34 1.84 [ 0.08, 43.98 ]
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.40. Comparison 1 All eligible infants, Outcome 40 Any visual disability in survivors at 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 40 Any visual disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 7/56 2/34 2.13 [ 0.47, 9.64 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.41. Comparison 1 All eligible infants, Outcome 41 Severe visual disability in survivors at 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 41 Severe visual disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 1/56 0/34 1.84 [ 0.08, 43.98 ]
0.02 0.1 1 10 50
Favours treatment Favours control
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Analysis 1.42. Comparison 1 All eligible infants, Outcome 42 Any hearing disability in survivors at 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 42 Any hearing disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 3/56 4/34 0.46 [ 0.11, 1.91 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.43. Comparison 1 All eligible infants, Outcome 43 Severe hearing disability in survivors at 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 43 Severe hearing disability in survivors at 7 years
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 0/56 0/34 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.44. Comparison 1 All eligible infants, Outcome 44 Days on ECMO.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 44 Days on ECMO
Study or subgroup ECMO conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 5.67 (5.49) 92 0.24 (2.29) 5.43 [ 4.22, 6.64 ]
-4 -2 0 2 4
Favours treatment Favours control
Analysis 1.45. Comparison 1 All eligible infants, Outcome 45 Days on > 90% oxygen.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 45 Days on > 90% oxygen
Study or subgroup ECMO Conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 1.48 (3.07) 92 3.56 (4.4) -2.08 [ -3.17, -0.99 ]
-2 -1 0 1 2
Favours treatment Favours control
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Analysis 1.46. Comparison 1 All eligible infants, Outcome 46 Days on ventilator.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 46 Days on ventilator
Study or subgroup ECMO Conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 6.25 (13.72) 92 3.95 (8.55) 2.30 [ -0.99, 5.59 ]
-4 -2 0 2 4
Favours treatment Favours control
Analysis 1.47. Comparison 1 All eligible infants, Outcome 47 Days on supplementary oxygen at any
concentration.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 47 Days on supplementary oxygen at any concentration
Study or subgroup ECMO conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 15.91 (39.84) 92 8.87 (37.65) 7.04 [ -4.13, 18.21 ]
-10 -5 0 5 10
Favours treatment Favours control
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Analysis 1.48. Comparison 1 All eligible infants, Outcome 48 Days on standard neonatal care.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 48 Days on standard neonatal care
Study or subgroup ECMO Conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 10.32 (19.29) 92 4.23 (7.99) 6.09 [ 1.84, 10.34 ]
-10 -5 0 5 10
Favours treatment Favours control
Analysis 1.49. Comparison 1 All eligible infants, Outcome 49 Days in hospital (initial admission).
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 49 Days in hospital (initial admission)
Study or subgroup ECMO Conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 39.62 (58.43) 92 20.85 (45.1) 18.77 [ 3.74, 33.80 ]
-20 -10 0 10 20
Favours treatment Favours control
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Analysis 1.50. Comparison 1 All eligible infants, Outcome 50 Number of ambulance journeys.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 50 Number of ambulance journeys
Study or subgroup ECMO conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 1.9 (1.3) 92 0.43 (0.65) 1.47 [ 1.17, 1.77 ]
-1 -0.5 0 0.5 1
Favours treatment Favours control
Analysis 1.51. Comparison 1 All eligible infants, Outcome 51 Days in hospital (all re-admissions up to 7
years).
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 51 Days in hospital (all re-admissions up to 7 years)
Study or subgroup ECMO conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 4.37 (12.38) 92 3.32 (8.49) 1.05 [ -2.01, 4.11 ]
-4 -2 0 2 4
Favours treatment Favours control
41Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.52. Comparison 1 All eligible infants, Outcome 52 Number of hospital outpatient visits up to 7
years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 52 Number of hospital outpatient visits up to 7 years
Study or subgroup ECMO conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 13.16 (29.52) 92 7.21 (20.12) 5.95 [ -1.32, 13.22 ]
-10 -5 0 5 10
Favours treatment Favours control
Analysis 1.53. Comparison 1 All eligible infants, Outcome 53 Number of family doctor visits up to 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 53 Number of family doctor visits up to 7 years
Study or subgroup ECMO conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 23.01 (29.95) 92 14.34 (27.19) 8.67 [ 0.43, 16.91 ]
-10 -5 0 5 10
Favours treatment Favours control
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Analysis 1.54. Comparison 1 All eligible infants, Outcome 54 Number of health visitor visits up to 7 years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 54 Number of health visitor visits up to 7 years
Study or subgroup ECMO conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 10.83 (1.92) 92 7.38 (11.72) 3.45 [ 1.02, 5.88 ]
-4 -2 0 2 4
Favours treatment Favours control
Analysis 1.55. Comparison 1 All eligible infants, Outcome 55 Number of visits by other professionals up to 7
years.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 55 Number of visits by other professionals up to 7 years
Study or subgroup ECMO Conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 13.58 (32.39) 92 20.03 (85.85) -6.45 [ -25.19, 12.29 ]
-20 -10 0 10 20
Favours treatment Favours control
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Analysis 1.56. Comparison 1 All eligible infants, Outcome 56 Total health service costs (£GB 2003 prices).
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 1 All eligible infants
Outcome: 56 Total health service costs ( GB 2003 prices)
Study or subgroup ECMO conventional
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
UK 1996 93 30270 (24380) 92 10229 (18356) 20041.00 [ 13826.45, 26255.55 ]
-100 -50 0 50 100
Favours treatment Favours control
Analysis 2.1. Comparison 2 Infants without congenital diaphragmatic hernia as principal diagnosis,
Outcome 1 Death before discharge home.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 2 Infants without congenital diaphragmatic hernia as principal diagnosis
Outcome: 1 Death before discharge home
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boston 1989 0/9 4/10 8.5 % 0.12 [ 0.01, 2.00 ]
Michigan 1985 0/10 1/1 5.1 % 0.06 [ 0.00, 1.02 ]
Syracuse 1992 1/15 6/13 12.8 % 0.14 [ 0.02, 1.05 ]
UK 1996 15/75 37/75 73.6 % 0.41 [ 0.24, 0.67 ]
Total (95% CI) 109 99 100.0 % 0.33 [ 0.21, 0.53 ]
Total events: 16 (ECMO), 48 (Conventional)
Heterogeneity: Chi2 = 3.17, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 4.58 (P < 0.00001)
0.005 0.1 1 10 200
Favours treatment Favours control
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Analysis 2.2. Comparison 2 Infants without congenital diaphragmatic hernia as principal diagnosis,
Outcome 2 Death in the first year of life.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 2 Infants without congenital diaphragmatic hernia as principal diagnosis
Outcome: 2 Death in the first year of life
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Syracuse 1992 2/15 6/13 14.8 % 0.29 [ 0.07, 1.19 ]
UK 1996 17/75 37/75 85.2 % 0.46 [ 0.29, 0.74 ]
Total (95% CI) 90 88 100.0 % 0.43 [ 0.28, 0.68 ]
Total events: 19 (ECMO), 43 (Conventional)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00029)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 2.3. Comparison 2 Infants without congenital diaphragmatic hernia as principal diagnosis,
Outcome 3 Death at any time to the end of data collection.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 2 Infants without congenital diaphragmatic hernia as principal diagnosis
Outcome: 3 Death at any time to the end of data collection
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boston 1989 0/9 4/10 8.5 % 0.12 [ 0.01, 2.00 ]
Michigan 1985 0/10 1/1 5.1 % 0.06 [ 0.00, 1.02 ]
Syracuse 1992 2/15 6/13 12.8 % 0.29 [ 0.07, 1.19 ]
UK 1996 18/75 37/75 73.6 % 0.49 [ 0.31, 0.77 ]
Total (95% CI) 109 99 100.0 % 0.41 [ 0.27, 0.63 ]
Total events: 20 (ECMO), 48 (Conventional)
Heterogeneity: Chi2 = 3.25, df = 3 (P = 0.36); I2 =8%
Test for overall effect: Z = 4.11 (P = 0.000039)
0.005 0.1 1 10 200
Favours treatment Favours control
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Analysis 2.4. Comparison 2 Infants without congenital diaphragmatic hernia as principal diagnosis,
Outcome 4 Severe disability in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 2 Infants without congenital diaphragmatic hernia as principal diagnosis
Outcome: 4 Severe disability in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 1/58 1/37 0.64 [ 0.04, 9.89 ]
0.05 0.2 1 5 20
Favours treatment Favours control
Analysis 2.5. Comparison 2 Infants without congenital diaphragmatic hernia as principal diagnosis,
Outcome 5 Disability (severe and not severe) in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 2 Infants without congenital diaphragmatic hernia as principal diagnosis
Outcome: 5 Disability (severe and not severe) in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Syracuse 1992 2/13 1/7 17.6 % 1.08 [ 0.12, 9.89 ]
UK 1996 10/58 5/37 82.4 % 1.28 [ 0.47, 3.44 ]
Total (95% CI) 71 44 100.0 % 1.24 [ 0.50, 3.07 ]
Total events: 12 (ECMO), 6 (Conventional)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 2.6. Comparison 2 Infants without congenital diaphragmatic hernia as principal diagnosis,
Outcome 6 Death or severe disability at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 2 Infants without congenital diaphragmatic hernia as principal diagnosis
Outcome: 6 Death or severe disability at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 17/75 38/75 0.45 [ 0.28, 0.72 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 2.7. Comparison 2 Infants without congenital diaphragmatic hernia as principal diagnosis,
Outcome 7 Death or severe disability at 4 years of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 2 Infants without congenital diaphragmatic hernia as principal diagnosis
Outcome: 7 Death or severe disability at 4 years of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 18/75 37/75 0.49 [ 0.31, 0.77 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 3.1. Comparison 3 Infants with congenital diaphragmatic hernia as principal diagnosis, Outcome 1
Death before discharge home.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 3 Infants with congenital diaphragmatic hernia as principal diagnosis
Outcome: 1 Death before discharge home
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 13/18 17/17 0.73 [ 0.54, 0.98 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 3.2. Comparison 3 Infants with congenital diaphragmatic hernia as principal diagnosis, Outcome 2
Death in the first year of life.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 3 Infants with congenital diaphragmatic hernia as principal diagnosis
Outcome: 2 Death in the first year of life
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 14/18 17/17 0.78 [ 0.60, 1.02 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 3.3. Comparison 3 Infants with congenital diaphragmatic hernia as principal diagnosis, Outcome 3
Death at any time to the end of data collection.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 3 Infants with congenital diaphragmatic hernia as principal diagnosis
Outcome: 3 Death at any time to the end of data collection
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 15/18 17/17 0.84 [ 0.67, 1.05 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 3.4. Comparison 3 Infants with congenital diaphragmatic hernia as principal diagnosis, Outcome 4
Death or severe disability at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 3 Infants with congenital diaphragmatic hernia as principal diagnosis
Outcome: 4 Death or severe disability at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 14/18 17/17 0.78 [ 0.60, 1.02 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 3.5. Comparison 3 Infants with congenital diaphragmatic hernia as principal diagnosis, Outcome 5
Death or severe disability at 4 years of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 3 Infants with congenital diaphragmatic hernia as principal diagnosis
Outcome: 5 Death or severe disability at 4 years of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 16/18 17/17 0.89 [ 0.74, 1.08 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
Analysis 4.1. Comparison 4 Infants with oxygenation index 40-60 at trial entry, Outcome 1 Severe disability
in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 4 Infants with oxygenation index 40-60 at trial entry
Outcome: 1 Severe disability in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 0/42 0/25 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 4.2. Comparison 4 Infants with oxygenation index 40-60 at trial entry, Outcome 2 Disability
(severe and not severe) in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 4 Infants with oxygenation index 40-60 at trial entry
Outcome: 2 Disability (severe and not severe) in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 8/42 3/25 1.59 [ 0.46, 5.44 ]
0.2 0.5 1 2 5
Favours treatment Favours control
Analysis 4.3. Comparison 4 Infants with oxygenation index 40-60 at trial entry, Outcome 3 Death or severe
disability at 4 years of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 4 Infants with oxygenation index 40-60 at trial entry
Outcome: 3 Death or severe disability at 4 years of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 15/55 29/55 0.52 [ 0.31, 0.85 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
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Analysis 5.1. Comparison 5 Infants with oxygenation index > 60 at trial entry, Outcome 1 Severe disability
in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 5 Infants with oxygenation index > 60 at trial entry
Outcome: 1 Severe disability in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 1/20 1/12 0.60 [ 0.04, 8.73 ]
0.05 0.2 1 5 20
Favours treatment Favours control
Analysis 5.2. Comparison 5 Infants with oxygenation index > 60 at trial entry, Outcome 2 Disability (severe
and not severe) in survivors at one year of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 5 Infants with oxygenation index > 60 at trial entry
Outcome: 2 Disability (severe and not severe) in survivors at one year of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 5/20 2/12 1.50 [ 0.34, 6.56 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 5.3. Comparison 5 Infants with oxygenation index > 60 at trial entry, Outcome 3 Death or severe
disability at 4 years of age.
Review: Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants
Comparison: 5 Infants with oxygenation index > 60 at trial entry
Outcome: 3 Death or severe disability at 4 years of age
Study or subgroup ECMO Conventional Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
UK 1996 19/37 25/37 0.76 [ 0.52, 1.12 ]
0.5 0.7 1 1.5 2
Favours treatment Favours control
WH A T ’ S N E W
Last assessed as up-to-date: 1 November 2007.
Date Event Description
10 March 2008 Amended Converted to new review format.
2 November 2007 New search has been performed This updates the review “Extracorporeal membrane
oxygenation for severe respiratory failure in newborn
infants” published in The Cochrane Database of Sys-
tematic Reviews, Issue 1, 2002 (Elbourne 2002).
Based on an updated search in November 2007, no
new trials have been reported, but there is new data on
clinical followupdata at seven years (including resource
use) from the largest trial
2 November 2007 New citation required but conclusions have not
changed
The conclusion that ECMO is an effective interven-
tion for eligible babies is not changed by the new data:
ECMO increases survival without severe disability. Al-
though overall resource use is also increased, cost effec-
tiveness, estimated for the UK context, is within the
accepted range for neonatal technologies
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